Among the 303 LCH patients with MAP2K1 or other BRAF alterations, patients with the MAP2K1 mutation had a higher prevalence of single‐system bone involvement (SS‐bone) than patients carrying the BRAF mutation (p = 0.0072). The gene discussed is MAP2K1; the disease is Langerhans cell histiocytosis.